Business
Xeris Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that, in connection with its previously announced underwritten public offering of shares of common stock, the underwriters partially exercised their option to purchase an additional 1,299,769 shares of common stock from the Company out of the 1,350,000 total shares underlying the option. The exercise of this option increased the size of the offering to an aggregate of 10,299,769 shares at a price to the public of $4.15 per share. The aggregate gross proceeds of the offering were approximately $42.7 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase of additional shares of common stock closed on February 20, 2020.\n\n\nJefferies, Piper Sandler, RBC Capital Markets and Mizuho Securities acted as joint book running managers for the offering.\n\n\nThe shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-233061), including a base prospectus, filed by Xeris on August 6, 2019 and declared effective by the Securities and Exchange Commission, or SEC, on August 21, 2019. A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on February 13, 2020 and is available at the SEC’s website at www.sec.gov. A copy of the final prospectus supplement and accompanying prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by email at [email protected]; Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402; by phone at (800) 747-3924; or by email at [email protected]; RBC Capital Markets, LLC, Attention: Equity Syndicate Department, 200 Vesey Street, 8th Floor, New York, NY 10281; by phone at (877) 822-4089; or by email at [email protected]; or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020; by phone at (212) 205-7600; or by email at [email protected].\n\n\nThis press re...